Feed

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid tumors due to its dense desmoplastic stroma, poor vascular perfusion, and the limited intratumoral delivery of chemotherapeutic agents such as oxaliplatin (OXA). Extracellular vesicles (EVs) offer a biocompatible platform for drug delivery, yet their intrinsic lack of tumor specificity constrains therapeutic efficacy. Ephrin type-A receptor 2 (EphA2), which is highly expressed and efficiently internalized in PDAC, represents an attractive molecular target for guiding EVs into tumor cells. In this study, we engineered HEK293T-derived EVs to display membrane-anchored anti-EphA2 Fab fragments and encapsulate OXA (EVs-EphA2/OXA) as a targeted delivery system for PDAC therapy. Stable producer cells expressed the engineered Fab on the plasma membrane and released vesicles that retained canonical EV markers and robust antigen-binding capability. EVs-EphA2 demonstrated selective uptake into EphA2-positive AsPC-1 and BxPC-3 cells and induced significantly greater cytotoxicity than free OXA or untargeted EVs/OXA in vitro. In xenograft models, EVs-EphA2/OXA achieved the most pronounced tumor suppression, accompanied by increased γH2AX-associated DNA damage, enhanced TUNEL-positive apoptosis, and preferential tumor accumulation in biodistribution imaging. These findings demonstrate that EphA2-targeted EVs can substantially improve intratumoral delivery of OXA and amplify antitumor efficacy, supporting EVs-EphA2/OXA as a promising platform for receptor-guided chemotherapy in PDAC.